Piramal Enterprises has received approval to raise up to Rs 100 crore along with an option to retain over subscription of up to Rs 650 crore, aggregating up to Rs 750 crore through the issuance of Secured, Rated, Listed, Redeemable, Principal Protected, Market Linked Non-Convertible Debentures (Debentures) on private placement basis. Debentures are proposed to be listed on Debt Segment and Capital Market Segment of National Stock Exchange (‘NSE’) and BSE, respectively. The Meeting of Administrative Committee of the Board of Directors held on September 20, 2022 approved the same.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
